FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2976278991> ?p ?o ?g. }

• W2976278991 endingPage "122" @default.
• W2976278991 startingPage "113" @default.
• W2976278991 abstract "Non-small cell lung cancer (NSCLC) is the most common type of lung cancer, accounting for 80-85% of cases. Epidermal growth factor receptor (EGFR) mutations are observed in approximately 40% and 20% of patients with NSCLC in Asian and non-Asian populations, respectively. First-generation (gefitinib, erlotinib) and second-generation (afatinib, dacomitinib) EGFR-tyrosine kinase inhibitors (TKIs) have been standard-of-care (SoC) first-line treatment for patients with sensitizing EGFR mutation positive advanced NSCLC following Phase III trials versus platinum-based doublet chemotherapy. However, most patients treated with first-line first- or second-generation EGFR-TKIs develop resistance. Osimertinib, a third-generation, central nervous system active EGFR-TKI which potently and selectively inhibits both EGFR-TKI sensitizing (EGFRm) and the most common EGFR T790 M resistance mutations, has shown superior efficacy versus first-generation EGFR-TKIs (gefitinib / erlotinib). Osimertinib is now a treatment option for patients with advanced NSCLC harboring EGFRm in the first-line setting, and treatment of choice for patients with T790 M positive NSCLC following disease progression on first-line EGFR-TKIs. The second-generation EGFR-TKI dacomitinib has also recently been approved for the first-line treatment of EGFRm positive metastatic NSCLC. There remains a need to determine appropriate sequencing of EGFR-TKIs in this setting, including EGFR-TKIs as monotherapy or in combination with other TKIs / signaling pathway inhibitors. This review considers the evolving role of sequencing treatments to maximize benefits for patients with EGFRm positive advanced NSCLC." @default.
• W2976278991 created "2019-10-03" @default.
• W2976278991 creator A5020870134 @default.
• W2976278991 creator A5029627466 @default.
• W2976278991 creator A5063199354 @default.
• W2976278991 date "2019-11-01" @default.
• W2976278991 modified "2023-10-14" @default.
• W2976278991 title "Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC)" @default.
• W2976278991 cites W1546552389 @default.
• W2976278991 cites W1574226582 @default.
• W2976278991 cites W1584059175 @default.
• W2976278991 cites W1842992197 @default.
• W2976278991 cites W1892652546 @default.
• W2976278991 cites W1908940658 @default.
• W2976278991 cites W1942770305 @default.
• W2976278991 cites W1980497534 @default.
• W2976278991 cites W1984004254 @default.
• W2976278991 cites W1986412478 @default.
• W2976278991 cites W1988827171 @default.
• W2976278991 cites W1988856925 @default.
• W2976278991 cites W1996865879 @default.
• W2976278991 cites W1998971866 @default.
• W2976278991 cites W2000948841 @default.
• W2976278991 cites W2003984225 @default.
• W2976278991 cites W2014484940 @default.
• W2976278991 cites W2022670843 @default.
• W2976278991 cites W2026342389 @default.
• W2976278991 cites W2027735722 @default.
• W2976278991 cites W2040561412 @default.
• W2976278991 cites W2063391304 @default.
• W2976278991 cites W2065607022 @default.
• W2976278991 cites W2074791509 @default.
• W2976278991 cites W2076466060 @default.
• W2976278991 cites W2088540000 @default.
• W2976278991 cites W2096198395 @default.
• W2976278991 cites W2098395191 @default.
• W2976278991 cites W2101329867 @default.
• W2976278991 cites W2101581271 @default.
• W2976278991 cites W2110841878 @default.
• W2976278991 cites W2111662961 @default.
• W2976278991 cites W2114095518 @default.
• W2976278991 cites W2123918574 @default.
• W2976278991 cites W2125665528 @default.
• W2976278991 cites W2126177831 @default.
• W2976278991 cites W2128385295 @default.
• W2976278991 cites W2129360604 @default.
• W2976278991 cites W2129656399 @default.
• W2976278991 cites W2131407638 @default.
• W2976278991 cites W2132540363 @default.
• W2976278991 cites W2132870547 @default.
• W2976278991 cites W2133149289 @default.
• W2976278991 cites W2135192471 @default.
• W2976278991 cites W2138089710 @default.
• W2976278991 cites W2138536086 @default.
• W2976278991 cites W2139799027 @default.
• W2976278991 cites W2143913849 @default.
• W2976278991 cites W2146418087 @default.
• W2976278991 cites W2149733252 @default.
• W2976278991 cites W2152905269 @default.
• W2976278991 cites W2154149901 @default.
• W2976278991 cites W2154662831 @default.
• W2976278991 cites W2156560090 @default.
• W2976278991 cites W2159013299 @default.
• W2976278991 cites W2160725767 @default.
• W2976278991 cites W2160982674 @default.
• W2976278991 cites W2163351155 @default.
• W2976278991 cites W2171139285 @default.
• W2976278991 cites W2210071992 @default.
• W2976278991 cites W2259143567 @default.
• W2976278991 cites W2284844200 @default.
• W2976278991 cites W2315951931 @default.
• W2976278991 cites W2328294134 @default.
• W2976278991 cites W2339311613 @default.
• W2976278991 cites W2342296008 @default.
• W2976278991 cites W2346744024 @default.
• W2976278991 cites W2352491315 @default.
• W2976278991 cites W2394669266 @default.
• W2976278991 cites W2400274474 @default.
• W2976278991 cites W2464433500 @default.
• W2976278991 cites W2468983064 @default.
• W2976278991 cites W2475230058 @default.
• W2976278991 cites W2476256861 @default.
• W2976278991 cites W2490543344 @default.
• W2976278991 cites W2513491150 @default.
• W2976278991 cites W2513563720 @default.
• W2976278991 cites W2529337595 @default.
• W2976278991 cites W2530508394 @default.
• W2976278991 cites W2536396512 @default.
• W2976278991 cites W2554688226 @default.
• W2976278991 cites W2560717039 @default.
• W2976278991 cites W2568475650 @default.
• W2976278991 cites W2575565717 @default.
• W2976278991 cites W2587420003 @default.
• W2976278991 cites W2591118779 @default.
• W2976278991 cites W2594811626 @default.
• W2976278991 cites W2595324731 @default.
• W2976278991 cites W2597231917 @default.
• W2976278991 cites W2607454228 @default.

• next